<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05058404</url>
  </required_header>
  <id_info>
    <org_study_id>FIL_FOLL19</org_study_id>
    <nct_id>NCT05058404</nct_id>
  </id_info>
  <brief_title>Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma</brief_title>
  <official_title>Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma. A Randomized, Open Label, Phase III Study by Fondazione Italiana Linfomi.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Italiana Linfomi ONLUS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Italiana Linfomi ONLUS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      FIL_FOLL19 is an open-label, multicenter, randomized phase III trial. The sponsor of this&#xD;
      clinical trial is Fondazione Italiana Linfomi (FIL).&#xD;
&#xD;
      The Primary Objective of the study is to demonstrate that, in patients with newly diagnosed,&#xD;
      advanced stage Follicular Lymphoma (FL) with high tumor burden according to the Groupe&#xD;
      d'Etude des Lymphomes Folliculaires (GELF) criteria, a treatment strategy that reduces the&#xD;
      number of chemotherapy cycles in case of early response to immunochemotherapy is not inferior&#xD;
      compared to standard therapy at full dose in terms of Progression-Free Survival (PFS).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, multicenter, randomized phase III trial. The study plans to randomize&#xD;
      patients with a 1:1 ratio to Arm A (Standard arm) or Arm B (Experimental arm).&#xD;
&#xD;
      Once randomized, each patient will start immunochemotherapy with one of the approved regimens&#xD;
      (R-CHOP, R-Bendamustine, G-CHOP, G-Bendamustine, G-CVP) chosen by the physician on a patient&#xD;
      basis before randomization.&#xD;
&#xD;
      Patients randomized to Arm A will receive an induction immunochemotherapy at full doses&#xD;
      (standard schedule).&#xD;
&#xD;
      After cycle 4, patients will be assessed for response and will complete their planned therapy&#xD;
      if at least a stable disease is confirmed.&#xD;
&#xD;
      Patients randomized to Arm B will start their induction treatment with 4 cycles of the&#xD;
      immunochemotherapy standard dose chosen by the physician: after cycle 4, patients will be&#xD;
      assessed for response and will proceed with subsequent treatment based on the quality of&#xD;
      their response.&#xD;
&#xD;
      Specifically:&#xD;
&#xD;
        -  Patients achieving a Complete Remission (CR) will receive a shortened treatment: in&#xD;
           detail, they won't receive any further chemotherapy but will complete induction with 4&#xD;
           additional cycles of only the Monoclonal Antibody (MoAb) given during the first four&#xD;
           cycles (in case of G-bendamustine, 2 additional cycles of obinutuzumab);&#xD;
&#xD;
        -  In case if response less than Complete Remission (CR), Partial Remission (PR) or Stable&#xD;
           Disease (SD), patients will complete treatment as planned for patients in Arm A.&#xD;
&#xD;
      In both arms, at the end of induction responding patients (CR, PR) will be addressed to a&#xD;
      standard anti-CD20 maintenance (1 dose every 8 weeks for two years) with the same Monoclonal&#xD;
      Antibody (MoAb) given during induction.&#xD;
&#xD;
      Patients with progressive disease at any time (regardless of treatment arm) will be addressed&#xD;
      to salvage therapy.&#xD;
&#xD;
      The study plans the evaluation of quality of life by collecting the Patient-Reported&#xD;
      Outcome(s) (PROs) through the Functional Assessment of Cancer Treatment-Lymphoma (FACT-Lym&#xD;
      questionnaire) at predetermined timepoints during the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">July 2030</completion_date>
  <primary_completion_date type="Anticipated">July 2028</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a prospective, multicenter, phase III, two arms randomized trial with a non-inferiority design with Progression-Free Survival (PFS) as primary endpoint. Patients who meet all eligibility criteria will be centrally randomized to one of the two treatment arms in a 1:1 ratio, using random sequences blocks of variable size. The web-based allocation process, completely concealed to researchers, will be stratified according Follicular Lymphoma International Prognostic Index 2 (FLIPI2) score (0-2, 3-5), chemotherapy regimen (CHOP, Bendamustine, CVP) and anti-CD20 Monoclonal Antibody (MoAb) (rituximab, obinutuzumab). A non-inferiority design has been adopted to demonstrate that a shortened exposure to chemotherapy in patients responding to the first four cycles of immunochemotherapy is not detrimental in terms of PFS compared to full dose standard treatment. The primary comparison will be done as an Intention To Treat (ITT) analysis including all randomized patients.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>The endpoint will be assessed from the beginning of the study up to 104 months (end of study)</time_frame>
    <description>The length of time during and after the treatment that patients live with the disease, but it does not get worse. Progression-Free Survival (PFS) will be measured from the time of study entry to documented progression or to the patient's death as a result of any causes. Subjects with incomplete follow-up or with no disease evaluation will be censored at the date of last available documented status of freedom from failure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>The endpoint will be assessed from the beginning of the study up to 104 months (end of study)</time_frame>
    <description>Overall Survival, the percentage of patients alive, will be measured from the time of study entry to death from any cause. Patients who have not died at the time of the final analysis will be censored at the date of the last contact.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-Free Survival (EFS)</measure>
    <time_frame>The endpoint will be assessed from the beginning of the study up to 104 months (end of study)</time_frame>
    <description>The measure of time after treatment that patients have not have cancer come back or get worse. It will be measured from the time of study entry to any treatment failure, including disease progression, or discontinuation of treatment for any reason (e.g., disease progression, toxicity, patient preference, initiation of a new treatment without documented progression) or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response rate (ORR)</measure>
    <time_frame>The endpoint will be assessed from the beginning of the study up to 104 months (end of study)</time_frame>
    <description>Overall response rate (ORR) is defined as the proportion of patients who have a partial or complete response to therapy; It will be defined according to Response Criteria for Non-Hodgkin Lymphoma (NHL) with Positron Emission Tomography (PET) (Lugano 2014). ORR will include the sum of patients in Complete Remission and Partial Remission (CR + PR). It will be evaluated on assessed patients and on all treated patients, considering patients without a response assessment (due to any reason) as non-responders.&#xD;
The best overall response will be defined as the best response between the date of beginning of therapy and the last restaging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response rate (CRR)</measure>
    <time_frame>The endpoint will be assessed from the beginning of the study up to 104 months (end of study)</time_frame>
    <description>The Complete Response Rate is defined as the percentage of patient in Complete Remission. It will be defined according to Response Criteria for Non-Hodgkin Lymphoma (NHL) with Positron Emission Tomography (PET) (Lugano 2014). CRR will include only patients in Complete Remission (CR). It will be evaluated on assessed patients and on all treated patients, considering patients without a response assessment (due to any reason) as non-responders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular response</measure>
    <time_frame>The endpoint will be assessed from the beginning of the study up to 104 months (end of study)</time_frame>
    <description>Molecular response assessed by means of the evaluation of the Bcl2/IgH rearrangement at baseline and of the Minimal Residual Disease (MRD) at subsequent defined timepoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of toxicities (Safety of the treatment)</measure>
    <time_frame>The endpoint will be assessed from the beginning of the study up to 104 months (end of study)</time_frame>
    <description>Safety of the treatment according to the current version of the CTCAE. Incidence of toxicities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-Reported Outcomes (PROs)</measure>
    <time_frame>The endpoint will be assessed from the beginning of the study up to 104 months (end of study)</time_frame>
    <description>Health Related Quality of Life (HR-QoL) will be evaluated by means of Patient-Reported Outcome(s) PROs. Patients will be asked to complete the Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym) questionnaire at prespecified points during the study. The questionnaire results will be analyzed according to recommendations of the instrument scoring procedures.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">602</enrollment>
  <condition>Follicular Lymphoma</condition>
  <arm_group>
    <arm_group_label>Standard arm (A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will start immunochemotherapy with one of the approved regimens (R-CHOP, R-Bendamustine, G-CHOP, G-Bendamustine, G-CVP).&#xD;
Patients randomized to Arm A will receive an induction immunochemotherapy at full doses (standard schedule).&#xD;
After cycle 4, patients will be assessed for response and will complete their planned therapy if at least a stable disease is confirmed.&#xD;
At the end of induction responding patients (CR, PR) will be addressed to a standard anti-CD20 maintenance (1 dose every 8 weeks for two years) with the same Monoclonal Antibody (MoAb) given during induction.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental arm (B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will start immunochemotherapy with one of the approved regimens (R-CHOP, R-Bendamustine, G-CHOP, G-Bendamustine, G-CVP).&#xD;
Patients randomized to Arm B will start their induction treatment with 4 cycles of the immunochemotherapy standard dose chosen by the physician: after cycle 4, patients will be assessed for response and will proceed with subsequent treatment based on the quality of their response. Specifically:&#xD;
Patients achieving a CR will receive a shortened treatment: in detail, they won't receive any further chemotherapy but will complete induction with 4 additional cycles of only the Monoclonal Antibody (MoAb) given during the first four cycles;&#xD;
In case if response less than CR, (PR,SD), patients will complete treatment as planned for patients in Arm A.&#xD;
At the end of induction responding patients (CR, PR) will be addressed to a standard anti-CD20 maintenance (1 dose every 8 weeks for two years) with the same Monoclonal Antibody (MoAb) given during induction.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immunochemotherapy regimen: Rituximab-bendamustine (Arm A)</intervention_name>
    <description>Arm A (Standard arm):&#xD;
4 cycles of Rituximab-bendamustine Q28 (28-days cycles); Patients will undergo an early restaging after cycle 4: those with at least a stable disease will complete the induction treatment with 2 cycles of R-bendamustine Q28 + 2 cycles Q28 of rituximab;&#xD;
Both Arms:&#xD;
Whichever the regimen, in responding patients (Complete Remission CR, Partial Remission PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 Monoclonal Antibody (MoAb) used for induction.&#xD;
Patients in both arms with progressive disease at any time and patients in stable disease (SD) at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion.</description>
    <arm_group_label>Standard arm (A)</arm_group_label>
    <other_name>R-Benda, R-bendamustine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immunochemotherapy regimen: Rituximab-bendamustine (Arm B)</intervention_name>
    <description>Arm B (Experimental arm):&#xD;
4 cycles of Rituximab-bendamustine Q28 (28-days cycles);&#xD;
After cycle 4 patients will undergo an early restaging. Induction therapy shall be completed based on the response achieved and on the treatment chosen as below specified:&#xD;
if in CR: patients will receive no more chemotherapy but will complete induction with the MoAb only, in this case: 4 cycles of rituximab;&#xD;
if less than CR (PR, SD): the immunochemotherapy program will be completed as outlined for Arm A: 2 cycles of R-bendamustine Q28 + 2 cycles Q28 of rituximab;&#xD;
Both Arms:&#xD;
Whichever the regimen, in responding patients (CR, PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 Monoclonal Antibody (MoAb) used for induction.&#xD;
Patients in both arms with progressive disease at any time and patients in SD at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion.</description>
    <arm_group_label>Experimental arm (B)</arm_group_label>
    <other_name>R-Benda, R-bendamustine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immunochemotherapy regimen: R-CHOP (Arm A)</intervention_name>
    <description>Arm A (Standard arm):&#xD;
4 cycles of R-CHOP Q21 (21-days cycles); R-CHOP = Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone&#xD;
Patients will undergo an early restaging after cycle 4: those with at least a stable disease will complete the induction treatment with 2 cycles of R-CHOP Q21 + 2 cycles Q21 of rituximab;&#xD;
Both Arms:&#xD;
Whichever the regimen, in responding patients (Complete Remission CR, Partial Remission PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 Monoclonal Antibody (MoAb) used for induction.&#xD;
Patients in both arms with progressive disease at any time and patients in stable disease (SD) at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion: these patients will be included in the analysis planned by the study.</description>
    <arm_group_label>Standard arm (A)</arm_group_label>
    <other_name>R-CHOP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immunochemotherapy regimen: R-CHOP (Arm B)</intervention_name>
    <description>Arm B (Experimental arm):&#xD;
4 cycles of R-CHOP Q21 (21-days cycles); R-CHOP = Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone&#xD;
After cycle 4 patients will undergo an early restaging: induction therapy shall be completed based on the response achieved and on the treatment chosen:&#xD;
if in CR: patients will receive no more chemotherapy but will complete induction with the MoAb only, in this case: 4 cycles of rituximab;&#xD;
if less than CR (PR, SD): the immunochemotherapy program will be completed as outlined for Arm A: 2 cycles of R-CHOP Q21+ 2 cycles Q21of rituximab&#xD;
Both Arms: in responding patients (CR, PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 MoAb used for induction.&#xD;
Patients in both arms with progressive disease at any time and patients in SD at the EOI shall be considered for salvage therapy at clinician discretion: these patients will be included in the analysis.</description>
    <arm_group_label>Experimental arm (B)</arm_group_label>
    <other_name>R-CHOP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immunochemotherapy regimen: G-bendamustine (Arm A)</intervention_name>
    <description>Arm A (Standard arm):&#xD;
4 cycles of G-bendamustine Q28 (28-days cycles); G-Bendamustine = Obinutuzumab and Bendamustine&#xD;
Patients will undergo an early restaging after cycle 4: those with at least a stable disease will complete the induction treatment with 2 cycles of G-bendamustine Q28 (28-days cycles);&#xD;
Both Arms:&#xD;
Whichever the regimen, in responding patients (Complete Remission CR, Partial Remission) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 Monoclonal Antibody (MoAb) used for induction.&#xD;
Patients in both arms with progressive disease at any time and patients in Stable Disease SD at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion.</description>
    <arm_group_label>Standard arm (A)</arm_group_label>
    <other_name>G-Benda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immunochemotherapy regimen: G-bendamustine (Arm B)</intervention_name>
    <description>Arm B (Experimental arm):&#xD;
4 cycles of G-bendamustine Q28 (28-days cycles); G-Bendamustine = Obinutuzumab and Bendamustine&#xD;
After cycle 4 patients will undergo an early restaging. Induction therapy shall be completed based on the response achieved and on the treatment chosen as below specified:&#xD;
if in CR: patients will receive no more chemotherapy but will complete induction with the Monoclonal Antibody (MoAb) only, in this case 2 cycles of obinutuzumab;&#xD;
if less than CR (PR, SD): the immunochemotherapy program will be completed as outlined for Arm A: 2 cycles of G-bendamustine Q28;&#xD;
Both Arms: in responding patients (CR, PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 (MoAb) used for induction.&#xD;
Patients in both arms with progressive disease at any time and patients in SD at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion.</description>
    <arm_group_label>Experimental arm (B)</arm_group_label>
    <other_name>G-Benda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immunochemotherapy regimen: G-CHOP (Arm A)</intervention_name>
    <description>Arm A (Standard arm):&#xD;
4 cycles of G-CHOP Q21 (21-days cycles) G-CHOP = Obinutuzumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone&#xD;
Patients will undergo an early restaging after cycle 4: those with at least a stable disease will complete the induction treatment with 2 cycles of G-CHOP Q21 + 2 cycles Q21 of obinutuzumab;&#xD;
Both Arms:&#xD;
Whichever the regimen, in responding patients (Complete Remission CR, Partial Remission PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 Monoclonal Antibody (MoAb) used for induction.&#xD;
Patients in both arms with progressive disease at any time and patients in stable disease (SD) at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion.</description>
    <arm_group_label>Standard arm (A)</arm_group_label>
    <other_name>G-CHOP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immunochemotherapy regimen: G-CHOP (Arm B)</intervention_name>
    <description>4 cycles of G-CHOP Q21 (21-days cycles) G-CHOP = Obinutuzumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone&#xD;
After cycle 4 patients will undergo an early restaging. Induction therapy shall be completed based on the response achieved and on the treatment chosen as below specified:&#xD;
if in CR: patients will receive no more chemotherapy but will complete induction with the Monoclonal Antibody (MoAb) only, in this case: 4 cycles of obinutuzumab;&#xD;
if less than CR (PR, SD): the immunochemotherapy program will be completed as outlined for Arm A: 2 cycles of G-CHOP Q21 + 2 cycles Q21 of obinutuzumab;&#xD;
Both Arms: in responding patients (CR, PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 MoAb used for induction.&#xD;
Patients in both arms with progressive disease at any time and patients in SD at the EOI shall be considered for salvage therapy at clinician discretion.</description>
    <arm_group_label>Experimental arm (B)</arm_group_label>
    <other_name>G-CHOP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immunochemotherapy regimen: G-CVP (Arm A)</intervention_name>
    <description>Arm A (Standard arm):&#xD;
4 cycles of G-CVP Q21 (21-days cycles) G-CVP = Obinutuzumab, Cyclophosphamide, Vincristine, Prednisone.&#xD;
Patients will undergo an early restaging after cycle 4: those with at least a stable disease will complete the induction treatment with 4 cycles of G-CVP Q21;&#xD;
Both Arms:&#xD;
Whichever the regimen, in responding patients (Complete Remission CR, Partial Remission PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 Monoclonal Antibody (MoAb) used for induction.&#xD;
Patients in both arms with progressive disease at any time and patients in stable disease SD at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion.</description>
    <arm_group_label>Standard arm (A)</arm_group_label>
    <other_name>G-CVP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immunochemotherapy regimen: G-CVP (Arm B)</intervention_name>
    <description>Arm B (Experimental arm):&#xD;
4 cycles of G-CVP Q21 (21-days cycles) G-CVP = Obinutuzumab, Cyclophosphamide, Vincristine, Prednisone.&#xD;
After cycle 4 patients will undergo an early restaging. Induction therapy shall be completed based on the response achieved and on the treatment chosen as below specified:&#xD;
if in CR: patients will receive no more chemotherapy but will complete induction with the Monoclonal Antibody (MoAb) only, in this case: 4 cycles of obinutuzumab;&#xD;
if less than CR (PR, SD): the immunochemotherapy program will be completed as outlined for Arm A: 4 cycles of G-CVP Q21&#xD;
Both Arms: in responding patients (CR, PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 MoAb used for induction.&#xD;
Patients in both arms with progressive disease at any time and patients in SD at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion.</description>
    <arm_group_label>Experimental arm (B)</arm_group_label>
    <other_name>G-CVP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically documented diagnosis of CD20+ Follicular lymphoma grade 1-2 or 3a, as&#xD;
             defined in the 2017 edition of the World Health Organization (WHO) classification;&#xD;
&#xD;
          2. Age ≥ 18 years;&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) performance status 0-2 (Appendix B);&#xD;
&#xD;
          4. No previous immunochemotherapy for the lymphoma (localized radiotherapy or rituximab&#xD;
             monotherapy with max of 4 doses are allowed);&#xD;
&#xD;
          5. Ann Arbor stage II-IV (Appendix A);&#xD;
&#xD;
          6. High tumor burden as per Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria&#xD;
             defined as the presence of at least one of the following:&#xD;
&#xD;
               -  systemic symptoms;&#xD;
&#xD;
               -  Tumor bulk (any nodal or extranodal tumor mass with diameter &gt; 7 cm);&#xD;
&#xD;
               -  involvement of ≥ 3 nodal sites, each with a diameter ≥ 3 cm;&#xD;
&#xD;
               -  splenomegaly;&#xD;
&#xD;
               -  compressive syndrome (organ compression);&#xD;
&#xD;
               -  serous effusion;&#xD;
&#xD;
               -  circulant malignant cells;&#xD;
&#xD;
               -  cytopenia;&#xD;
&#xD;
               -  Eastern Cooperative Oncology Group - Performance Status (ECOG-PS) &gt; 1;&#xD;
&#xD;
               -  Lactate dehydrogenase (LDH) &gt; upper limit of normality (ULN);&#xD;
&#xD;
               -  β2-microglobulin &gt; 3 mg/L.&#xD;
&#xD;
          7. At least one site of measurable nodal disease at baseline ≥ 1.5 cm in the longest&#xD;
             transverse diameter as determined by CT scan (MRI is allowed if CT scan cannot be&#xD;
             performed); or evaluable disease at baseline FDG-PET (18F-fluorodeoxyglucose&#xD;
             (FDG)-Positron Emission Tomography (PET)) scan (at least one metabolic active site of&#xD;
             disease);&#xD;
&#xD;
          8. Adequate hematological counts (unless due to bone marrow involvement by lymphoma)&#xD;
             defined as follows:&#xD;
&#xD;
               1. Absolute Neutrophil count (ANC) &gt; 1.5 x 109/L;&#xD;
&#xD;
               2. Platelet count ≥ 80 x 109/L ;&#xD;
&#xD;
               3. Hemoglobin ≥ 10 g/dL.&#xD;
&#xD;
          9. Adequate renal function defined as creatinine ≤ 2 mg/dL, unless secondary to lymphoma;&#xD;
&#xD;
         10. Adequate hepatic function defined as bilirubin ≤ 2 mg/dL, unless secondary to&#xD;
             lymphoma;&#xD;
&#xD;
         11. Left Ventricular Ejection Fraction (LVEF) &gt; 50% at bidimensional echocardiogram&#xD;
             (mandatory only for patients receiving R/G-CHOP);&#xD;
&#xD;
         12. Life expectancy ≥ 6 months;&#xD;
&#xD;
         13. Subject understands and voluntarily signs an informed consent form approved by an&#xD;
             Independent Ethics Committee (IEC) prior to the initiation of any screening or&#xD;
             study-specific procedures;&#xD;
&#xD;
         14. Subject must be able to adhere to the study visit schedule and other protocol&#xD;
             requirements;&#xD;
&#xD;
         15. Women of childbearing potential (WOCBP) and men must agree to use effective&#xD;
             contraception if sexually active. This applies for the time period between signing of&#xD;
             the informed consent form and 12 months after last rituximab dose or 18 months after&#xD;
             last obinutuzumab dose. A woman is considered of childbearing potential, i.e. fertile,&#xD;
             following menarche and until becoming postmenopausal unless permanently sterile.&#xD;
             Permanent sterilization methods include but are not limited to hysterectomy, bilateral&#xD;
             salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no&#xD;
             menses for continuous 12 months without an alternative medical cause. A high follicle&#xD;
             stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a&#xD;
             postmenopausal state in women not using hormonal contraception or hormonal replacement&#xD;
             therapy. The investigator or a designated associate is requested to advise the patient&#xD;
             how to achieve highly effective birth control (failure rate of less than 1%) e.g.,&#xD;
             intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral&#xD;
             tubal occlusion, vasectomized partner. The use of condoms by male patients is required&#xD;
             (even if surgically sterilized, i.e., status post vasectomy) unless the female partner&#xD;
             is permanently sterile. Full sexual abstinence is admitted when this is in line with&#xD;
             the preferred and usual lifestyle of the subject, for the same time period planned for&#xD;
             other methods of birth control (see above). Periodic abstinence (e.g., calendar,&#xD;
             ovulation, symptothermal, post ovulation methods for the female partner) and&#xD;
             withdrawal are not acceptable methods of contraception).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Histological diagnosis different from FL grade 1-3a WHO 2017 classification;&#xD;
&#xD;
          2. Suspect or clinical evidence of Central Nervous System (CNS) involvement by lymphoma;&#xD;
&#xD;
          3. Contraindication to the use of anti-CD20 monoclonal antibodies;&#xD;
&#xD;
          4. Subject has received any anticancer therapy (chemotherapy, immunotherapy,&#xD;
             investigational therapy, including targeted small molecule agents) within 14 days&#xD;
             prior to the first dose of study drug;&#xD;
&#xD;
          5. Noteworthy history of neurologic, psychiatric, endocrinological, metabolic,&#xD;
             immunologic, or hepatic disease that would preclude participation in the study or&#xD;
             compromise ability to give informed consent;&#xD;
&#xD;
          6. Any history of other active malignancies within 3 years prior to study entry, with the&#xD;
             exception of: adequately treated in situ carcinoma of the cervix uterine; basal cell&#xD;
             carcinoma of the skin or localized squamous cell carcinoma of the skin; limited stage&#xD;
             surgically removed breast cancer or adequately treated with radiation therapy; limited&#xD;
             stage prostate carcinoma surgically removed or adequately treated with radiation&#xD;
             therapy; previous malignancy confined and surgically resected with curative intent;&#xD;
&#xD;
          7. Evidence of other clinically significant uncontrolled condition(s) including, but not&#xD;
             limited to:&#xD;
&#xD;
               -  Uncontrolled and/or active systemic infection (viral, bacterial or fungal),&#xD;
                  including active ongoing infection from SARS-CoV-2;&#xD;
&#xD;
               -  Chronic or acute hepatitis B (HBV) or hepatitis C (HCV) requiring treatment.&#xD;
                  Note: subjects with serologic evidence of prior vaccination to HBV (i.e., HBsAg&#xD;
                  negative, HBsAb positive and HBcAb negative) or positive HBcAb from previous&#xD;
                  infection or intravenous immunoglobulins (IVIG) may participate; inactive&#xD;
                  carriers (HBsAg positive with undetectable HBV- DNA) are eligible. Patients with&#xD;
                  presence of HCV antibody are eligible only if Polymerase Chain Reaction (PCR)&#xD;
                  negative for HCV-RNA;&#xD;
&#xD;
          8. Women who are pregnant or breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefano Luminari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Reggio Emilia - Azienda Unitа Sanitaria Locale-IRCCS - Arcispedale Santa Maria Nuova - Ematologia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antonella Ferranti</last_name>
    <phone>0131033153</phone>
    <email>aferranti@filinf.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alessandra Dondi</last_name>
    <phone>0599769910</phone>
    <email>adondi@filinf.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ospedale &quot;Monsignor Raffaele Dimiccoli&quot; - Ematologia</name>
      <address>
        <city>Barletta</city>
        <state>Barletta Andria Trani</state>
        <zip>76121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Giuseppe Tarantini, MD</last_name>
      <email>giuseppetarantini0@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Giuseppe Tarantini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Casa Sollievo della Sofferenza - U.O. Ematologia</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <state>Foggia</state>
        <zip>71013</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Nicola Cascavilla, MD</last_name>
      <email>n.cascavilla@operapadrepio.it</email>
    </contact>
    <investigator>
      <last_name>Nicola Cascavilla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Romagnolo per lo studio dei Tumori &quot;Dino Amadori&quot; - IRST S.R.L. - Ematologia</name>
      <address>
        <city>Meldola</city>
        <state>Forlì - Cesena</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Eliana Valentina Liardo, MD</last_name>
      <email>eliana.liardo@irst.emr.it</email>
    </contact>
    <investigator>
      <last_name>Eliana Valentina Liardo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. C. Panico - U.O.C Ematologia e Trapianto</name>
      <address>
        <city>Tricase</city>
        <state>Lecce</state>
        <zip>73039</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Vincenzo Pavone, MD</last_name>
      <email>salentoematologia@piafondazionepanico.it</email>
    </contact>
    <investigator>
      <last_name>Vincenzo Pavone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nuovo Ospedale Civile di Sassuolo - Day Hospital Oncologico</name>
      <address>
        <city>Sassuolo</city>
        <state>Modena</state>
        <zip>41049</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Sara Bigliardi, MD</last_name>
      <email>s.bigliardi@ausl.mo.it</email>
    </contact>
    <investigator>
      <last_name>Sara Bigliardi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASST MONZA Ospedale S. Gerardo - Ematologia</name>
      <address>
        <city>Monza</city>
        <state>Monza E Brianza</state>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Bolis Silvia, MD</last_name>
      <email>s.bolis@asst-monza.it</email>
    </contact>
    <investigator>
      <last_name>Silvia Bolis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Centro di Riferimento Oncologico di Aviano - Divisione di Oncologia e dei Tumori immuto-correlati</name>
      <address>
        <city>Aviano</city>
        <state>Pordenone</state>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Michele Spina, MD</last_name>
      <email>mspina@cro.it</email>
    </contact>
    <investigator>
      <last_name>Michele Spina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Presidio ospedaliero &quot;A. TORTORA&quot; - U.O. Onco-ematologia</name>
      <address>
        <city>Pagani</city>
        <state>Salerno</state>
        <zip>84016</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Catello Califano, MD</last_name>
      <email>c.califano@aslsalerno.it</email>
    </contact>
    <investigator>
      <last_name>Catello Califano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione del Piemonte per l'Oncologia - IRCCS - Ematologia</name>
      <address>
        <city>Candiolo</city>
        <state>Torino</state>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Delia Rota Scalabrini, MD</last_name>
      <email>delia.rotascalabrini@ircc.it</email>
    </contact>
    <investigator>
      <last_name>Delia Rota Scalabrini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale di Castelfranco Veneto - Ematologia</name>
      <address>
        <city>Castelfranco Veneto</city>
        <state>Treviso</state>
        <zip>31033</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Roberto Sartori, MD</last_name>
      <email>roberto.sartori@iov.veneto.it</email>
    </contact>
    <investigator>
      <last_name>Roberto Sartori, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASST Valle Olona - Ospedale di Circolo di Busto Arsizio - S.C. Ematologia</name>
      <address>
        <city>Busto Arsizio</city>
        <state>Varese</state>
        <zip>21052</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Fabrizio Ciambelli, MD</last_name>
      <email>ciambelli@libero.it</email>
    </contact>
    <investigator>
      <last_name>Fabrizio Ciambelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Dell'Angelo - U.O. Ematologia</name>
      <address>
        <city>Mestre</city>
        <state>Venezia</state>
        <zip>30174</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Renato Bassan, MD</last_name>
      <email>renato.bassan@aulss3.veneto.it</email>
    </contact>
    <investigator>
      <last_name>Renato Bassan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USLL13 - Dipartimento di Scienze Mediche UOC di Oncologia ed Ematologia Oncologica</name>
      <address>
        <city>Mirano</city>
        <state>Venezia</state>
        <zip>30035</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Giovanni Bertoldero, MD</last_name>
      <email>giovanni.bertoldero@ulss13mirano.ven.it</email>
    </contact>
    <investigator>
      <last_name>Giovanni Bertoldero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. SS. Antonio e Biagio e Cesare Arrigo - S.C. Ematologia</name>
      <address>
        <city>Alessandria</city>
        <zip>15121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Manuela Zanni, MD</last_name>
      <email>manuela.zanni@ospedale.al.it</email>
    </contact>
    <investigator>
      <last_name>Manuela Zanni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU Ospedali Riuniti - Clinica di Ematologia</name>
      <address>
        <city>Ancona</city>
        <zip>60126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Attilio Olivieri, MD</last_name>
      <email>a.olivieri@univpm.it</email>
    </contact>
    <investigator>
      <last_name>Attilio Olivieri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale C.e G. Mazzoni - U.O.C. di Ematologia</name>
      <address>
        <city>Ascoli Piceno</city>
        <zip>63100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Piero Galieni, MD</last_name>
      <email>piero.galieni@sanita.marche.it</email>
    </contact>
    <investigator>
      <last_name>Piero Galieni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera S.Giuseppe Moscati - S.C. Ematologia e Trapianto emopoietico</name>
      <address>
        <city>Avellino</city>
        <zip>83100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Sonya De Lorenzo, MD</last_name>
      <email>sonya.delorenzo@tin.it</email>
    </contact>
    <investigator>
      <last_name>Sonya De Lorenzo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU Policlinico Consorziale - U.O. Ematologia con Trapianto</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Pellegrino Musto, MD</last_name>
      <email>pellegrino.musto@uniba.it</email>
    </contact>
    <investigator>
      <last_name>Pellegrino Musto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Martino - UOC Oncologia</name>
      <address>
        <city>Belluno</city>
        <zip>32100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Fable Zustovich, MD</last_name>
      <email>fable.zustovich@aulss1.veneto.it</email>
    </contact>
    <investigator>
      <last_name>Fable Zustovich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.R.N. Gaetano Rummo - DH Ematologico</name>
      <address>
        <city>Benevento</city>
        <zip>82100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Roberto Vallone, MD</last_name>
      <email>rbtvallone@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Roberto Vallone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cliniche Humanitas Gavazzeni - Oncologia - Cliniche Humanitas Gavazzeni</name>
      <address>
        <city>Bergamo</city>
        <zip>24125</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Serena Camilla Dalto, MD</last_name>
      <email>serena.dalto@gavazzeni.it</email>
    </contact>
    <investigator>
      <last_name>Serena Camilla Dalto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nuovo Ospedale degli Infermi - SSD Ematologia</name>
      <address>
        <city>Biella</city>
        <zip>13875</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Annarita Conconi, MD</last_name>
      <email>annarita.conconi@aslbi.piemonte.it</email>
    </contact>
    <investigator>
      <last_name>Annarita Conconi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Antonio Perrino - U.O. Ematologia e Trapianti di Midollo</name>
      <address>
        <city>Brindisi</city>
        <zip>72100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Domenico Pastore, MD</last_name>
      <email>domenico.pastore0@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Domenico Pastore, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero - Universitaria Policlinico - Vittorio Emanuele Presidio Ospedale Ferrarotto - Ematologia</name>
      <address>
        <city>Catania</city>
        <zip>95125</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Francesco Di Raimondo, MD</last_name>
      <email>diraimon@unict.it</email>
    </contact>
    <investigator>
      <last_name>Francesco Di Raimondo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU Mater Domini - Università - U.O. Oncologia</name>
      <address>
        <city>Catanzaro</city>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Marco Rossi, MD</last_name>
      <email>rossim@unicz.it</email>
    </contact>
    <investigator>
      <last_name>Marco Rossi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Cosenza - UOC Ematologia</name>
      <address>
        <city>Cosenza</city>
        <zip>87100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Massimo Gentile, MD</last_name>
      <email>massimogentile@virgilio.it</email>
    </contact>
    <investigator>
      <last_name>Massimo Gentile, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria di Ferrara - Arcispedale Sant'Anna - Ematologia e fisiopatologia della coagulazione</name>
      <address>
        <city>Ferrara</city>
        <zip>44124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Antonio Cuneo, MD</last_name>
      <email>cut@unife.it</email>
    </contact>
    <investigator>
      <last_name>Antonio Cuneo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Careggi - Unitа funzionale di Ematologia</name>
      <address>
        <city>Firenze</city>
        <zip>50141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Benedetta Puccini, MD</last_name>
      <email>puccinib@aou-careggi.toscana.it</email>
    </contact>
    <investigator>
      <last_name>Benedetta Puccini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Giovanni di Dio - SOS Ematologia clinica e oncoematologia ASL Toscana Centro</name>
      <address>
        <city>Firenze</city>
        <zip>50143</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Sabrina Moretti, MD</last_name>
      <email>sabrina.moretti@uslcentro.toscana.it</email>
    </contact>
    <investigator>
      <last_name>Sabrina Moretti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Policlinico San Martino S.S.R.L. - IRCCS per l Oncologia - Ematologia</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Chiara Ghiggi, MD</last_name>
      <email>chiara.ghiggi@hsanmartino.it</email>
    </contact>
    <investigator>
      <last_name>Chiara Ghiggi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Vito Fazzi - Ematologia</name>
      <address>
        <city>Lecce</city>
        <zip>73100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Nicola Di Renzo, MD</last_name>
      <email>direnzo.ematolecce@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Nicola Di Renzo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale di Livorno - Ematologia</name>
      <address>
        <city>Livorno</city>
        <zip>57124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Enrico Capochiani, MD</last_name>
      <email>e.capochiani@usl6.toscana.it</email>
    </contact>
    <investigator>
      <last_name>Enrico Capochiani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Madonna delle Grazie - Ematologia</name>
      <address>
        <city>Matera</city>
        <zip>75100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Clara Mannarella, MD</last_name>
      <email>clara.mannarella@virgilio.it</email>
    </contact>
    <investigator>
      <last_name>Clara Mannarella, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedali Riuniti Papardo-Piemonte - S.C. Ematologia</name>
      <address>
        <city>Messina</city>
        <zip>98158</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Donato Mannina, MD</last_name>
      <email>donamanni@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Donato Mannina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Maggiore Policlinico - Fondazione IRCCS Ca' Granda - Ematologia</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Gianluigi Reda, MD</last_name>
      <email>gianluigi.reda@policlinico.mi.it</email>
    </contact>
    <investigator>
      <last_name>Gianluigi Reda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico San Raffaele - Unitа Linfomi - Dipartimento Oncoematologia</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Andres Ferreri, MD</last_name>
      <email>andres.ferreri@hsr.it</email>
    </contact>
    <investigator>
      <last_name>Andres Ferreri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASST Santi Paolo e Carlo - Onco - Ematologia</name>
      <address>
        <city>Milano</city>
        <zip>20153</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Vittorio Montefusco, MD</last_name>
      <email>vittorio.montefusco@asst-santipaolocarlo.it</email>
    </contact>
    <investigator>
      <last_name>Vittorio Montefusco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASST Grande Ospedale Metropolitano Niguarda - SC Ematologia</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Vittorio Ruggero Zilioli, MD</last_name>
      <email>vittorioruggero.zilioli@ospedaleniguarda.it</email>
    </contact>
    <investigator>
      <last_name>Vittorio Ruggero Zilioli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU Universitа degli Studi della Campania Luigi Vanvitelli - Oncologia Medica ed Ematologia</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Antonello Sica, MD</last_name>
      <email>antonello.sica@fastwebnet.it</email>
    </contact>
    <investigator>
      <last_name>Antonello Sica, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU Maggiore della Caritа di Novara - SCDU Ematologia</name>
      <address>
        <city>Novara</city>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Gloria Margiotta, MD</last_name>
      <email>gloria.margiotta@med.uniupo.it</email>
    </contact>
    <investigator>
      <last_name>Gloria Margiotta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>I.R.C.C.S. Istituto Oncologico Veneto - Oncologia 1</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Silvia Finotto, MD</last_name>
      <email>silvia.finotto@iov.veneto.it</email>
    </contact>
    <investigator>
      <last_name>Silvia Finotto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU Policlinico Giaccone - Ematologia</name>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Salvatrice Mancuso, MD</last_name>
      <email>salvatrice.mancuso@unipa.it</email>
    </contact>
    <investigator>
      <last_name>Salvatrice Mancuso, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Ospedali Riuniti Villa Sofia-Cervello - Divisione di Ematologia</name>
      <address>
        <city>Palermo</city>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Caterina Patti, MD</last_name>
      <email>k.patti@villasofia.it</email>
    </contact>
    <investigator>
      <last_name>Caterina Patti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UO Ematologia e CTMO - AOU di Parma</name>
      <address>
        <city>Parma</city>
        <zip>43126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Francesca Re, MD</last_name>
      <email>fre@ao.pr.it</email>
    </contact>
    <investigator>
      <last_name>Francesca Re, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Policlinico S. Matteo di Pavia - Div. di Ematologia</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Luca Arcaini, MD</last_name>
      <email>luca.arcaini@unipv.it</email>
    </contact>
    <investigator>
      <last_name>Luca Arcaini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>P.O. Spirito Santo di Pescara - UOS Dipartimentale - Centro di diagnosi e Terapia dei linfomi</name>
      <address>
        <city>Pescara</city>
        <zip>65124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Elsa Pennese, MD</last_name>
      <email>elsapennese@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Elsa Pennese, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Guglielmo da Saliceto - U.O.Ematologia</name>
      <address>
        <city>Piacenza</city>
        <zip>29121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Annalisa Arcari, MD</last_name>
      <email>a.arcari@ausl.pc.it</email>
    </contact>
    <investigator>
      <last_name>Annalisa Arcari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU Pisana - U.O. Ematologia</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Sara Galimberti, MD</last_name>
      <email>sara.galimberti@med.unipi.it</email>
    </contact>
    <investigator>
      <last_name>Sara Galimberti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.R. &quot;San Carlo&quot; - U.O. Ematologia</name>
      <address>
        <city>Potenza</city>
        <zip>85100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Michele Cimminiello, MD</last_name>
      <email>miki-doc@virgilio.it</email>
    </contact>
    <investigator>
      <last_name>Michele Cimminiello, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Stefano - SOS Oncoematologia, ASL Toscana Centro</name>
      <address>
        <city>Prato</city>
        <zip>59100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Simone Santini, MD</last_name>
      <email>simone.santini@uslcentro.toscana.it</email>
    </contact>
    <investigator>
      <last_name>Simone Santini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale delle Croci - Ematologia</name>
      <address>
        <city>Ravenna</city>
        <zip>48121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Monica Tani, MD</last_name>
      <email>monica.tani@auslromagna.it</email>
    </contact>
    <investigator>
      <last_name>Monica Tani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Unitа Sanitaria Locale-IRCCS - Arcispedale Santa Maria Nuova - Ematologia</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Stefano Luminari, MD</last_name>
      <email>stefano.luminari@ausl.re.it</email>
    </contact>
    <investigator>
      <last_name>Stefano Luminari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale degli Infermi di Rimini - U.O. di Ematologia</name>
      <address>
        <city>Rimini</city>
        <zip>47923</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Anna Merli, MD</last_name>
      <email>anna.merli@auslromagna.it</email>
    </contact>
    <investigator>
      <last_name>Anna Merli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Tor Vergata - Ematologia</name>
      <address>
        <city>Roma</city>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Maria Cantonetti, MD</last_name>
      <email>cantonetti@med.uniroma2.it</email>
    </contact>
    <investigator>
      <last_name>Maria Cantonetti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Eugenio - UOC Ematologia</name>
      <address>
        <city>Roma</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Elisabetta Abruzzese, MD</last_name>
      <email>elisabetta.abruzzese@uniroma2.it</email>
    </contact>
    <investigator>
      <last_name>Elisabetta Abruzzese, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Camillo - Ematologia</name>
      <address>
        <city>Roma</city>
        <zip>00152</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Roberta Battistini, MD</last_name>
      <email>rbattistini@scamilloforlanini.rm.it</email>
    </contact>
    <investigator>
      <last_name>Roberta Battistini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Umberto I - Universitа &quot;La Sapienza&quot; - Istituto Ematologia -Dipartimento di Medicina Traslazionale e di Precisione</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Alessandro Pulsoni, MD</last_name>
      <email>alessandro.pulsoni@uniroma1.it</email>
    </contact>
    <investigator>
      <last_name>Alessandro Pulsoni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitа Cattolica S. Cuore - Ematologia</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Stefan Hohaus, MD</last_name>
      <email>stefan.hohaus@Unicatt.it</email>
    </contact>
    <investigator>
      <last_name>Stefan Hohaus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale di Rovigo - S.O.S. Oncoematologia</name>
      <address>
        <city>Rovigo</city>
        <zip>45100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Rossella Paolini, MD</last_name>
      <email>rossella.paolini@aulss5.veneto.it</email>
    </contact>
    <investigator>
      <last_name>Rossella Paolini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ematologia e Trapianti A.O. San Giovanni di Dio e Ruggi D Aragona - U.O. Ematologia</name>
      <address>
        <city>Salerno</city>
        <zip>84131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Carmine Selleri, MD</last_name>
      <email>cselleri@unisa.it</email>
    </contact>
    <investigator>
      <last_name>Carmine Selleri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU di Sassari - Ematologia</name>
      <address>
        <city>Sassari</city>
        <zip>07100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Claudio Fozza, MD</last_name>
      <email>cfozza@uniss.it</email>
    </contact>
    <investigator>
      <last_name>Claudio Fozza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU Senese - U.O.C. Ematologia</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Emanuele Cencini, MD</last_name>
      <email>cencioema@libero.it</email>
    </contact>
    <investigator>
      <last_name>Emanuele Cencini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera della Valtellina e della Valchiavenna P.O. Sondrio - Medicina Interna - Centro Malattie del Sangue P.O. Sondrio</name>
      <address>
        <city>Sondrio</city>
        <zip>23100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Andrea Maria Soccodato, MD</last_name>
      <email>andresocco@alice.it</email>
    </contact>
    <investigator>
      <last_name>Andrea Maria Soccodato, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. S. Maria di Terni - S.C. Oncoematologia</name>
      <address>
        <city>Terni</city>
        <zip>05100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Anna Marina Liberati, MD</last_name>
      <email>marina.liberati@unipg.it</email>
    </contact>
    <investigator>
      <last_name>Anna Marina Liberati, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.U. Citta della Salute e della Scienza di Torino - Ematologia Universitaria</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Federica Cavallo, MD</last_name>
      <email>f.cavallo@unito.it</email>
    </contact>
    <investigator>
      <last_name>Federica Cavallo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.U. Citta della Salute e della Scienza di Torino - S.C.Ematologia</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Carola Boccomini, MD</last_name>
      <email>cboccomini@cittadellasalute.to.it</email>
    </contact>
    <investigator>
      <last_name>Carola Boccomini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Giovanni Bosco - ASL Cittа di Torino - SSD di Ematologia e Malattie Trombotiche</name>
      <address>
        <city>Torino</city>
        <zip>10154</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Maria Pagliaro, MD</last_name>
      <email>maria.pagliaro@aslcittaditorino.it</email>
    </contact>
    <investigator>
      <last_name>Maria Pagliaro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Ca Foncello - S.C di Ematologia</name>
      <address>
        <city>Treviso</city>
        <zip>31100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Elisabetta Scarpa, MD</last_name>
      <email>elisabetta.scarpa@aulss2.veneto.it</email>
    </contact>
    <investigator>
      <last_name>Elisabetta Scarpa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI) - SC Ematologia</name>
      <address>
        <city>Trieste</city>
        <zip>34121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Francesco Zaja, MD</last_name>
      <email>francesco.zaja@asugi.sanita.fvg.it</email>
    </contact>
    <investigator>
      <last_name>Francesco Zaja, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 7, 2021</study_first_submitted>
  <study_first_submitted_qc>September 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2021</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>High tumor burden Follicular Lymphoma</keyword>
  <keyword>Shortened vs standard chemotherapy</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Initial treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

